On 17 December 2024, Eli Lilly announced that China’s National Medical Products Administration (NMPA) has approved its donanemab-azbt Kisunla® (350 mg/20 mL every four weeks injection for IV infusion) for the treatment of early symptomatic Alzheimer’s Disease (AD) in adults. This includes people with mild cognitive impairment as well as those with the mild dementia stage of AD who have confirmed amyloid pathology.
It is estimated that nearly 6% of people over the age of 65 in China are currently living with AD and related dementias, with nearly 11% over the age of 65 predicted to be living with AD by 2050.
This follows the approval of Kisunla® in the US in July 2024, Japan in September 2024 and the UK in October 2024.